Status:
COMPLETED
Efficacy of Gadoterate Meglumine in Diagnosis of Vascular Diseases Using MRA MRA
Lead Sponsor:
Northwestern University
Conditions:
Vascular Diseases
Eligibility:
All Genders
18-89 years
Brief Summary
The purpose of this study is to compare magnetic resonance angiography (MRA) using gadoterate meglumine to clinically obtained MRA using gadobutrol. The specific aims are to show: 1. Carotid, chest, ...
Detailed Description
In this study, we will assess the image quality and accuracy of MRA studies acquired using these two contrast agents. In the cases where Digital Subtraction Angiography (DSA) or CT angiography images ...
Eligibility Criteria
Inclusion
- Male or female subjects 18-89 years of age
- Suspected or diagnosed vascular disease
- Standard of care carotid, chest, or
- Willingness to undergo 1 research MRA with up to double dose gadoterate meglumine
- Able to complete the MR safety questionnaire
- Able to comprehend and provide informed consent in English
Exclusion
- • Allergy to gadolinium-containing contrast media
- Chronic, severe kidney disease
- eGFR \< 60mL/min/1.73m2
- Acute kidney injury
- Kidney or liver transplant within 8 weeks
- Contraindication to MRI (implanted device, claustrophobia, dyspnea precluding the ability to follow breath-hold instructions)
- Pregnant or breastfeeding women
- Adults unable to consent
- Individual who are not yet adults
- Prisoners
Key Trial Info
Start Date :
June 2 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2020
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT05199792
Start Date
June 2 2017
End Date
January 1 2020
Last Update
January 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yasmeen Khan
Chicago, Illinois, United States, 60611